To the Editor:

Although the respiratory system is the primary target of the coronavirus, studies have demonstrated a strong tropism to the central nervous system (CNS).^[@bib1],[@bib2]^ The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects cells by binding to the angiotensin-converting enzyme 2 (ACE2) receptor. This receptor is also found in the CNS and plays a crucial role in autoregulating cerebral perfusion pressure.^[@bib3],[@bib4]^ Additionally, epidemiological data demonstrated increased mortality due to cardiovascular and cerebrovascular diseases during flu pandemics due to a hypercoagulable state.^[@bib5],[@bib6]^ The triad of neuroinvasion of SARS-CoV-2, induction of hypercoagulable state,^[@bib5]^ and the inhibition of ACE2 blocking the formation of Angiotensin (1-7) serve as the pathophysiology for neurovascular insults.^[@bib3],[@bib4]^ We present a case series of coronavirus disease 2019 (COVID-19) patients from 2 health systems developing cerebrovascular insult.

METHODS {#sec2}
=======

Study Design {#sec2-1}
------------

Institutional Review Board (IRB) approved the study protocol and waived the need for informed consent. A retrospective analysis was conducted across 2 institutions between March 20 and April 10, 2020. Fourteen patients were identified with the diagnosis of cerebrovascular insult and COVID-19 infection. COVID-19 was diagnosed using reverse-transcriptase/polymerase-chain-reaction assays of nasopharyngeal samples for SARS-CoV-2. Medical charts were queried for baseline patient characteristics, comorbidities, COVID-19 symptoms, duration between COVID-19 symptoms and the neurological manifestation, cerebrovascular insult, National Institutes of Health Stroke Scale (NIHSS) at presentation, procedure details, and mortality.

Data Sharing Statement {#sec2-2}
----------------------

The relevant anonymized patient-level data are available on reasonable request from the authors.

Ethical Approval {#sec2-3}
----------------

All procedures performed in the studies involving human participants were per the ethical standards of the IRB or National Research Committee, and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed Consent {#sec2-4}
----------------

The study protocol was reviewed and approved by the Thomas Jefferson University Institutional Review Board. Following our institutional guidelines, all protected health information were removed, and individual patient consent was not required for the analysis of this case series.

RESULTS {#sec3}
=======

The total sample size was 14 patients. The mean age was 60.1 ± 11.1 yr, and 9 patients were males (64.3%). Six patients (42.8%) had no significant prior medical history. Seven patients (50.3%) had neurological insult as the initial manifestation of COVID-19. The average duration between the onset of COVID-19 symptoms and the cerebrovascular insult was 3.5 d (range: 0-17). The cerebrovascular pathologies were 12 cases of acute ischemic stroke (AIS) and 2 cases of sinus thrombosis. The mean NIHSS was 15.8 (range: 1-30), and all patients were treated within 6 h of symptoms onset. A total of 4 patients had carotid T occlusions, 2 had tandem occlusion (internal carotid artery \[ICA\] and middle cerebral artery \[MCA\] M1 occlusion), 1 patient had M1 and A2 occlusion, 2 patients had M1 occlusion, 2 patients had M2 occlusion, 2 patients had sinus thrombosis, and 1 patient had central retinal artery occlusion. Two patients developed hemorrhagic conversion requiring decompressive surgery. The mean duration of the mechanical thrombectomy (MT) procedures was 95.5 min (range: 17-428), and a favorable thrombolysis in cerebral infarction (TICI) score (\>2b) was achieved in all patients. The total mortality incidence was 6 (42.8%; [Table](#tbl1){ref-type="table"}).

###### 

Demographics, Procedure Details and Outcomes, and Laboratory Findings

  Patient characteristics                Patient 1                       Patient 2                  Patient 3                                   Patient 4                                   Patient 5                 Patient 6                                                Patient 7                 Patient 8                              Patient 9                  Patient 10                 Patient 11                 Patient 12                                 Patient 13                 Patient 14
  -------------------------------------- ------------------------------- -------------------------- ------------------------------------------- ------------------------------------------- ------------------------- -------------------------------------------------------- ------------------------- -------------------------------------- -------------------------- -------------------------- -------------------------- ------------------------------------------ -------------------------- --------------------------
                                         Demographics                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Age, yr                                70                              51                         55                                          62                                          69                        54                                                       48                        59                                     72                         77                         52                         38                                         62                         72
  Gender                                 Female                          Male                       Male                                        Female                                      Female                    Male                                                     Male                      Male                                   Female                     Female                     Male                       Male                                       Male                       Male
  Initial findings and hospital course                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Medical history                        A-Fib                           Heart disease              None                                        Heart disease, A-Fib                        HTN-DM-A-Fib              HTN                                                      None                      HTN                                    Lung disease, diabetes     Diabetes                   None                       None                                       Lung disease               None
  Diagnosed before or after procedure    Before                          Before                     After                                       After                                       After                     Before                                                   After                     Before                                 After                      After                      After                      Before                                     Before                     Before
  Symptoms at disease onset              Fever, cough, pneumonia, ARDS   Fever                      Fever, cough                                Fever                                       None                      Cough, Pneumonia                                         None                      None                                   Pneumonia, ARDS                                       Pneumonia                  Fever, pneumonia                           Pneumonia                  Cough, pneumonia
  Symptom onset to presentation          11 d                            4 d                                                                                                                0                         17                                                       0                         0                                      0                                                     14                         2                                          5                          5
  Pathology                              Stroke (M1-A2 occlusion)        Stroke (T occlusion)       Stroke (tandem ICA/M1 occlusion)            Stroke (tandem ICA/M1 occlusion)            Stroke (M2 occlusion)     Deep venous thrombosis (vein of Galen, straight sinus)   Stroke (M1 occlusion)     Stroke (CRAO due to a ICA occlusion)   Stroke (M1 occlusion)      Stroke (T occlusion)       Stroke (T occlusion)       Sinus thrombosis (sagittal and straight)   Stroke (T occlusion)       Stroke (M2 occlusion)
  NIHSS/H&H                              21                              15                         16                                          18                                          4                         26                                                       26                        1                                      15                         4                          21                         14                                         30                         10
  Management and treatment               Mechanical thromb-ectomy        Mechanical thromb-ectomy   Mechanical thrombectomy, hemicra-niectomy   Mechanical thrombectomy, hemicra-niectomy   Mechanical thrombectomy   Heparin                                                  Mechanical thrombectomy   LMWH                                   Mechanical thromb-ectomy   Mechanical thromb-ectomy   Mechanical thromb-ectomy   Mechanical thromb-ectomy                   Mechanical thromb-ectomy   Mechanical thromb-ectomy
  Procedures required intubation         Yes                             Yes                        Yes                                         Yes                                         No                        NA                                                       No                        NA                                     Yes                        Yes                        Yes                        Yes                                        Yes                        Yes
  Procedure duration (min)               66                              150                        45                                          20                                          17                        NA                                                       25                        NA                                     27                         428                        59                         254                                        37                         67
  TICI score                             3                               2b                         2b                                          3                                           3                         NA                                                       3                         NA                                     2c                         2c                         2b                         NA                                         3                          2c
  Mortality                              Yes                             Yes                        Still in hospital                           Still in hospital                           No                        Yes                                                      No                        NA                                     Yes                        No                         No                         Yes                                        Yes                        No
  Laboratory findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  White-cell count (x10^3^/uL)           **14.2**                        5.8                        **14.3**                                    6.8                                         **11**                    **7.8**                                                  **8.2**                   7.6                                    7.9                        **17.6**                   **12.8**                   **16.7**                                   **24.9**                   9.7
  Differential cell C (B/L)                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Abs. neutrophils C                                                     4.4                        **11.5**                                    4.6                                                                   6.4                                                      7.2                       4.7                                    6.2                        **15.5**                   **10.9**                   **14.2**                                   **20**                     **8.5**
  Abs. lymphocytes C                                                     0.9                        1.5                                         1.7                                                                   1.1                                                      0.6                       2                                      1.2                        1.2                        1.1                        0.5                                        1.8                        0.5
  Abs. monocytes C                                                       0.3                        0.9                                         0.3                                                                   0.2                                                      0.3                       0.8                                    0.4                        0.7                        0.7                        **1.7**                                    **2.5**                    0.6
  Platelet C (x10^3^/uL)                 415                             273                        **472**                                     130                                         234                       339                                                      237                       327                                    331                        379                        104                        141                                        **476**                    226
  Hemoglobin (g/dL)                      10.3                            11.5                       9.1                                         9                                           12.4                      14.4                                                     13.3                      13.1                                   11.6                       8.2                        12                         14.3                                       12.9                       13.5
  Albumin (g/dL)                         2.3                             1.2                        3.4                                         4.3                                         3.8                       3.7                                                      4.2                       4                                      3                          3.1                        2.9                        4.4                                        3                          3.4
  AST (IU/L)                             **65**                          31                         **213**                                     30                                          37                        **44**                                                   21                        38                                     **71**                     10                         18                         31                                         **55**                     **48**
  ALT (IU/L)                             **91**                          8                          **227**                                     17                                          29                        **67**                                                   44                        **88**                                 34                         17                         19                         27                                         **78**                     **46**
  LDH (IU/L)                             **586**                         **689**                    **478**                                     **265**                                                               **382**                                                  269                       **272**                                **430**                    179                        **267**                    **448**                                    **520**                    **474**
  Creatinine (mg/dL)                     0.57                            **3.77**                   1.1                                         0.72                                        0.78                      1.06                                                     0.84                      1                                      **1.4**                    0.78                       0.66                       0.9                                        0.88                       1.22
  eGFR (units)                           \>60                            30                         \>60                                        \>60                                        \>60                      \>60                                                     \>60                      \>60                                   35                         \>60                       \>60                       \>60                                       \>60                       58.4
  Creatine kinase (IU/L)                 58                                                         **388**                                                                                                           190                                                      151                       136                                    **317**                    78                         127                        **594**                                    70                         **226**
  Troponin T high sensitivity (ng/L)     16                                                                                                     \<6                                         \<6                       14                                                       10                        11                                     10                         10                         10                         6                                          **90**                     20
  PT (s)                                 **13.5**                        **15.7**                   **14.1**                                    **13.5**                                    13                        11.8                                                     12.2                      14.6                                   **13.5**                   12.5                       12.6                       **22.5**                                   **19.1**                   12.8
  aPTT (s)                               23                              36                         32                                          **\>120**                                   35                        25                                                       29                        33                                     **38.7**                   33.8                       34                         30.6                                       **41.3**                   26.9
  Fibrinogen (mg/dL)                     **719**                         **970**                    331                                                                                                               429                                                      243                       **545**                                **634**                    **654**                    235                        121                                        84                         
  [d]{.smallcaps}-dimer (ng/mL)          **9862**                        **2476**                   **995**                                                                                                           **5748**                                                 **6383**                  **450**                                **3.247**                  **256**                    **\>10 000**               **\>55 000**                               **\>10 000**               **360**
  Serum ferritin (ng/mL)                 **3500**                        **1085**                   **749**                                                                                                           **508**                                                  270                       **1785**                               204                        4.6                        **588.1**                  **785**                                    **1028**                   **2929**
  C-reactive protein (mg/dL)             **41.7**                        **21.6**                   **5.3**                                                                                                           0.6                                                      0.3                       **2.1**                                **72**                     **10.1**                   **11**                     **188**                                    **154**                    **94.4**
  Procalcitonin (ng/mL)                  **0.26**                        **6.23**                   **0.12**                                                                                                                                                                   0.05                                                             **0·38**                                              0.03                                                                  **0.11**                   **0.12**
  Interleukin-6 (pg/mL)                                                  **185.3**                  **49.19**                                                                                                                                                                  **9.2**                                                          **14**                     \<5                                                                                              **45**                     **870**

Abs.: absolute; ALT: alanine aminotransferase; A-Fib: atrial fibrillation; aPTT: activated partial-thromboplastin time; ARDS: acute respiratory distress syndrome; AST: aspartate aminotransferase; A2: second segment of anterior cerebral artery; C: count; CRAO: central retina artery occlusion, eGFR: estimated glomerular filtration rate; ICA: internal carotid artery; LDH: lactate dehydrogenase; M1: first segment of middle cerebral artery; M2: second segment of middle cerebral artery; NIHSS: National Institutes of Health Stroke Scale; PT: prothrombin time; T occlusion: terminus occlusion; TICI score: thrombolysis in cerebral infarction score; SAH: subarachnoid hemorrhage.

Bold values are above normal levels and red values are below normal levels.

DISCUSSION {#sec4}
==========

Despite the small sample size, the data demonstrate some unusual trends worth sharing, at least to draw awareness. First, the mean age of the population was 60 yr, 42% of the cohort was younger than 55, and 42% did not have any traditional cerebrovascular risk factors. Moreover, cerebrovascular insult was the primary manifestation of COVID-19 in patients who did not have the fulminant virus manifestations present. Occlusions occurred in multiple arterial territories and both on the arterial and on the venous sides; the latter are more challenging to treat, and the procedures require additional expertise. Selected procedures were more complex and challenging, requiring multiple attempts to retrieve the clot entirely due to the severe clot burden. Such an observation is evident in the relatively long procedure time compared to historical data. Also, mortality rates reached 42.8%, with TICI ≥2b achieved in all cases. Two patients developed hemorrhagic conversion requiring decompressive hemicraniectomy (Figure [1](#fig1){ref-type="fig"}).

![A patient in the seventh decade with a history of A-Fib on eliqus was being treated for COVID-19, and on the 11th day of treatment, the patient developed an acute neurological insult. Tissue plasminogen activator was not given because of anticoagulation, and head computed tomography (CT) did not show hemorrhage. The patient was transferred and underwent a mechanical thrombectomy procedure within 4 h and 18 min. The insult progressed into complete infarct, and the patient passed away 3 d later. **A**, Noncontrast axial view of brain CT scan showing no hemorrhage. **B**, Anteroposterior (AP) digital subtraction angiography (DCA) of a right ICA injection showing an M1 and an A2 occlusion. **C**, AP DCA showing complete revascularization of both vessels (TICI 3). **D**, Noncontrast axial view of the brain day 1 post mechanical thrombectomy showing the progression of the insult into a complete infarct.](nyaa254fig1){#fig1}

The level of causality between the SARS-CoV-2 and AIS is yet to be determined. However, maintaining a vigilant attitude is crucial, specifically if it leads to favorable outcomes. It is early to determine the exact impact of COVID-19 on the incidence of acute cerebrovascular diseases. The SARS-CoV-2 is neuroinvasive and neurovirulent (Figure [2](#fig2){ref-type="fig"}),^[@bib1],[@bib2]^ binds to ACE2 and reduces its downstream effect (Figure [3](#fig3){ref-type="fig"}),^[@bib3],[@bib4]^ and induces a hyperinflammatory response characterized by a cytokine storm (Figure [4](#fig4){ref-type="fig"}).^[@bib7]^ This leads to vasculitis,^[@bib10]^ increased sympathetic tone, arrhythmias, and a hypercoagulable state.

![**A**, Schematic diagram showing CNS access by the SARS-CoV-2 virus through the olfactory nerve. **B**, Schematic diagram showing CNS access by the SARS-CoV-2 hematogenous route via direct access or via a trojan. The SARS-CoV-2 virus can infect endothelial and glial cells.](nyaa254fig2){#fig2}

![Schematic diagram at the level of CNS endothelium showing the SARS-CoV-2 induced ACE2 receptor downregulation. This inhibits the conversion of angiotensin I and II into their active metabolites, Angiotensin (1-9) and Angiotensin (1-7), respectively. The decline in Angiotensin (1-7) levels leads to loss of neuroprotective effects and sympathetic hyperactivity.](nyaa254fig3){#fig3}

![Schematic diagram at the level of alveoli showing the SARS-CoV-2 virus binding to ACE2 receptor and infecting the pneumocyte. The immune system is activated, and a cascade of inflammatory reactions leads to a cytokine storm (triggered by an imbalanced response by type 1 and type 2 T helper cells).](nyaa254fig4){#fig4}

CONCLUSION {#sec5}
==========

Unusual trends have been seen in AIS patients who are COVID-19 positive; while it is too early to establish direct causality, our preliminary data can be used to raise awareness in the population. We are seeing younger patients with no risk factors presenting with AIS and MT procedures are more challenging to deal with. It is crucial in pandemic times to watch and follow closely noteworthy trends and investigate and report new findings.
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